Obama To Lift Ban on Funding for Stem Cell Research
Obama's executive order on Monday would free up federal funding for research.
WaPo: President Obama is planning to sign an executive order on Monday rolling back restrictions on federal funding of human embryonic stem cell research, according to sources close to the issue.
Although the exact wording of the order has not been revealed, the White House plans an 11 a.m. ceremony to sign the order repealing one of the most controversial steps taken by his predecessor, fulfilling one of Obama's eagerly anticipated campaign promises.
The move, long sought by scientists and patient advocates and opposed by religious groups, would enable the National Institutes of Health to consider requests from scientists to study hundreds of lines of cells that have been developed since the limitations were put in place -- lines that scientists and patient advocate say hold great hope for leading to cures for a host of major ailments....
Opponents have argued that research on human embryonic stem cells has become unnecessary because of scientific advances in the interim, including promising advances, making it crucial to continue to study those cells along with embryonic cells.
Some opponents have suggested that Obama might qualify his executive order to try to take the sting out of the move as part of his effort to find common ground on divisive issues. But proponents expect Obama will simply lift the restriction without caveats and let the NIH work out the details. In anticipation, the NIH has started drafting guidelines that would address the many ethical issues raised by the research, using as models templates compiled by the National Academy of Sciences and the International Society for Stem Cell Research.
Companies are ready to move:
WSJ: Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. The announcement caps more than a decade of advances in the company's labs and comes on the cusp of a widely expected shift in U.S. policy toward support of embryonic stem-cell research after years of official opposition.
"This is the dawn of a new era in medical therapeutics," said Thomas B. Okarma, Geron's president and chief executive officer. The hope that stem-cell therapy will repair and regenerate diseased organs and tissue "goes beyond what pills and scalpels can ever do."
Limits on stem-cell research, which prevented federal funding and were imposed by Congress and former President George W. Bush for ethical and religious reasons, have had a chilling effect on both academic and corporate research involving such cells. Proponents of stem-cell research say restrictions have delayed development of promising new treatments, while critics contend that harvesting stem cells from embryos destroys human life.
Embryonic stem cells, as their name suggests, are derived from embryos. Specifically, embryonic stem cells are derived from embryos that develop from eggs that have been fertilized in vitro—in an in vitro fertilization clinic—and then donated for research purposes with informed consent of the donors. They are not derived from eggs fertilized in a woman's body.
